Tagged with Pharma,

China Click here to register and download PharmaBoardroom’s latest report: Healthcare & Life Sciences Review: China.   From the world’s ninth largest pharma market in 2007 to its second-biggest merely 12 years later, China and its growth story are impossible to ignore. China now accounts for a significant share of revenues…

Rankings A new report from specialist pharma and biotech consultancy Novasecta explores how the world’s top 100 pharma companies are shaping the future of healthcare. Through an examination of the various business models and key value drivers being applied by the top 100, a picture emerges of the successful modern pharma…

Rankings A new report from specialist pharma and biotech consultancy Novasecta explores how the world’s top 100 pharma companies are shaping the future of healthcare. Novasecta’s Global 100 is based on total group revenues (2018) of all organisations that have pharmaceutical interests, with the aim of benchmarking industry performance in its fullest context.    …

Egypt Amir Ghattas, senior director of the MENA cluster at LEO Pharma, highlights how the company is raising awareness for dermatological diseases in Egypt, having adopted a highly patient-centric focus. He also explains how LEO Pharma’s recent acquisitions and internal restructuration has benefitted the regional operations in the MENA cluster.  …

France France is rediscovering its mojo. After a period of relative stagnation, the country’s highly strategic USD 65 billion healthcare and life sciences market is once again an attractive investment proposition. With Brexit uncertainties across the channel and populist tendencies souring the prospects of some of its neighbours, France – under…

France Jaques Chevallet, CEO of Arkopharma, a European leader in herbal medicines and dietary supplements, discusses the company’s development over recent years while sharing his assessment on the current condition of the natural health product market and the role it can play as a partner to preventative care and healthcare sustainability.…

Spain Having largely recovered from the impact of the global financial crisis and with several impressive fundamentals in place, Spain once again stands as one of Europe’s premier healthcare and life science investment destinations.   These fundamentals include a revamped market access process that puts the Iberian nation on a par…

France David Lescuyer, managing director of Skyepharma, a specialized CDMO, reflects on the past three years of the company as it transitioned from a drug delivery platform to a fully-fledged service provider leveraging agile solutions across the value chain. Lescuyer also shares his insights on the service sector and the most…

Turkey Turkey – home to an 80 million-strong population, a substantial pharmaceuticals market and a universal healthcare system that is the envy of its neighbours – stands as one of the most promising healthcare and life science investment destinations in its region. Topics covered in this report range from the successes…

GW Pharma Founded in 1998, GW Pharmaceuticals is a British biopharmaceutical company, best known for being the only company with a license to cultivate cannabis in the UK. True pioneers, they are the producers of Sativex and Epiodiolex, the former being the world’s first prescription medicine derived from the cannabis plant —…

Malaysia The growth of the Malaysian pharma market between 2006 and 2016. Pharmaceutical sales grew to over USD 2 billion by 2016, thanks in large part to a burgeoning prescription medicine segment.   The import and export of pharmaeuticals in Malaysia between 2006 and 2016. In 2016, the trade balance stood…

China China has expanded to be the second largest pharmaceutical market globally with USD 137 billion in total spending in 2018, but growth has slowed from a 19% CAGR in 2008–2013 to an 8% CAGR in 2013–2018 and is expected to continue to decline to 3-6% through 2023, as the below…